News Room
News Room
News Room
Harmony Biosciences Ranked Among Top 25 Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500™
Ranking attributed to 7,204% growth from fiscal year 2019 to 2022 PLYMOUTH MEETING, Pa., Nov. 15, 2023 /PRNewswire/ – Harmony Biosciences Holdings, Inc. ("Harmony" [...]
Evozyne Announces $81 Million Financing Round to Advance Generative AI for Therapeutic Discovery and Drug Development
New investor OrbiMed expects platform to reduce development time for novel treatments and therapeutic approaches CHICAGO - BUSINESS WIRE, September 27, 2023 – Evozyne [...]
Harmony Biosciences to Acquire Zynerba Pharmaceuticals, Inc.
Acquisition expands pipeline and diversifies portfolio to drive long-term growth Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with high unmet medical needs [...]
Harmony Biosciences Announces Jeffrey M. Dayno, M.D. Appointed President & Chief Executive Officer
– Dr. Dayno joins Harmony Biosciences Board of Directors – PLYMOUTH MEETING, PA, April 24, 2023 – Harmony Biosciences Holdings, Inc. (“Harmony” or the [...]
Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam for Tourette Syndrome
– Enrolled patients will receive medication for up to 24 weeks; 90 sites planned for North America and Europe – CHICAGO, March 1, 2023 [...]
Harmony Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
WAKIX® (pitolisant) Net Revenue Increased ~41% Year-over-Year to $128.3 Million for Fourth Quarter 2022; ~43% to $437.9 Million for Full Year 2022 Achieved Net [...]
